Targeted Degradation of Androgen Receptor for the Potential Treatment of Prostate Cancer.

Prostate cancer (PCa) is the fourth most commonly diagnosed cancer in the world. Antiandrogens treatments have eventually mostly induced resistant mutations in patients, and when higher dosages are administered, they might cause adverse effects, such as fatigue, back pain, and constipation. The present Patent Highlight provides PROTACs that degrade or inhibit the androgen receptor at low concentrations in a subject in need of treatment.